Healthcare provider profile · identity verified

Manisha Patel, MD

Internal Medicine · STUART, FL · NPI 1710470141

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	321	187
Amlodipine Besylate	Amlodipine Besylate	206	126
Gabapentin	Gabapentin	171	98
Losartan Potassium	Losartan Potassium	154	77
Diclofenac Sodium	Diclofenac Sodium	147	109
Fluticasone Propionate	Fluticasone Propionate	118	80
Tizanidine Hcl	Tizanidine Hcl	103	67
Trazodone Hcl	Trazodone Hcl	91	40
Albuterol Sulfate Hfa	Albuterol Sulfate	83	43
Rosuvastatin Calcium	Rosuvastatin Calcium	81	41
Lisinopril	Lisinopril	80	48
Metformin Hcl	Metformin Hcl	79	47
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	69	44
Glipizide	Glipizide	68	40
Omeprazole	Omeprazole	68	35
Ibuprofen	Ibuprofen	67	41
Pantoprazole Sodium	Pantoprazole Sodium	67	46
Ozempic	Semaglutide	64	16
Hydrochlorothiazide	Hydrochlorothiazide	59	36
Levothyroxine Sodium	Levothyroxine Sodium	59	31
Tamsulosin Hcl	Tamsulosin Hcl	58	40
Carvedilol	Carvedilol	56	39
Nifedipine Er	Nifedipine	55	30
Metoprolol Succinate	Metoprolol Succinate	53	36
Furosemide	Furosemide	51	30
Eliquis	Apixaban	44	15
Metformin Hcl Er	Metformin Hcl	42	22
Triamcinolone Acetonide	Triamcinolone Acetonide	41	28
Simvastatin	Simvastatin	38	17
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	35	21
Methylprednisolone	Methylprednisolone	33	29
Pioglitazone Hcl	Pioglitazone Hcl	30	18
Meloxicam	Meloxicam	28	21
Metoprolol Tartrate	Metoprolol Tartrate	27	17
Sildenafil Citrate	Sildenafil Citrate	27	suppressed
Mirtazapine	Mirtazapine	26	20
Pravastatin Sodium	Pravastatin Sodium	26	12
Alprazolam	Alprazolam	25	suppressed
Azithromycin	Azithromycin	23	21
Baclofen	Baclofen	22	13
Famotidine	Famotidine	22	17
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	22	11
Lactulose	Lactulose	22	14
Clopidogrel	Clopidogrel Bisulfate	21	15
Meclizine Hcl	Meclizine Hcl	21	14
Quetiapine Fumarate	Quetiapine Fumarate	20	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	20	14
Alendronate Sodium	Alendronate Sodium	19	13
Hydralazine Hcl	Hydralazine Hcl	19	14
Ondansetron Odt	Ondansetron	19	16
Potassium Chloride	Potassium Chloride	18	14
Sertraline Hcl	Sertraline Hcl	18	11
Citalopram Hbr	Citalopram Hydrobromide	17	11
Duloxetine Hcl	Duloxetine Hcl	17	11
Ezetimibe	Ezetimibe	17	suppressed
Januvia	Sitagliptin Phosphate	17	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	17	14
Prednisone	Prednisone	17	13
Donepezil Hcl	Donepezil Hcl	16	suppressed
Finasteride	Finasteride	16	suppressed
Bupropion Hcl Sr	Bupropion Hcl	15	suppressed
Montelukast Sodium	Montelukast Sodium	15	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	14	suppressed
Clonidine Hcl	Clonidine Hcl	14	suppressed
Farxiga	Dapagliflozin Propanediol	14	suppressed
Naproxen	Naproxen	14	13
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	14
Xarelto	Rivaroxaban	14	suppressed
Allopurinol	Allopurinol	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	13
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	13	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	13	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	13	suppressed
Multaq	Dronedarone Hcl	13	suppressed
Atenolol	Atenolol	12	suppressed
Dutasteride-Tamsulosin	Dutasteride/Tamsulosin Hcl	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Lorazepam	Lorazepam	12	suppressed
Memantine Hcl	Memantine Hcl	12	suppressed
Spironolactone	Spironolactone	12	suppressed
Glimepiride	Glimepiride	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error